Introduction
Clinical trial sponsors have been integrating AI into drug development workflows for years — patient stratification models, pharmacokinetic simulations, endpoint adjudication algorithms, real-world data analysis. What the January 2025 FDA draft guidance on AI in regulatory decision-making does is impose a structured evidentiary standard on that work.
The guidance — issued jointly by CDER, CBER, CDRH, CVM, and the Office of Inspections and Investigations — establishes a seven-step, risk-based credibility assessment framework that applies whenever an AI model produces data or information intended to support a regulatory decision regarding the safety, effectiveness, or quality of a drug or biological product. Understanding how that framework operates, and what it requires of sponsors, is the operational challenge this guidance creates.
Section 1 — Scope: Where the Framework Applies and Where It Does Not
The guidance draws a precise boundary. AI used for operational efficiency — internal workflows, resource allocation, drafting regulatory submissions — falls outside its scope. The framework applies specifically when AI model outputs are used to produce data or information that supports regulatory decision-making.
That distinction is meaningful in practice. An AI tool that helps a clinical operations team prioritize monitoring visits is out of scope. An AI model that analyzes clinical trial data to support an efficacy or safety determination in a submission is fully within it. A model used to process real-world data for endpoint development, stratify patients for risk-based monitoring decisions, or conduct pharmacokinetic and exposure-response analyses is subject to the full framework.
The guidance explicitly names these in-scope use cases: reducing animal-based pharmacokinetic and toxicologic studies, predictive modeling for clinical pharmacokinetics, integrating natural history and registry data to characterize disease, processing large real-world datasets for endpoint development, and identifying postmarketing adverse events. Each of these requires a credibility assessment commensurate with the risk the model introduces into the decision it supports.
Section 2 — The Model Risk Matrix: Two Factors, One Determination
The core analytical tool in the guidance is the model risk matrix. Model risk is determined by the interaction of two independently assessed factors: model influence and decision consequence.
Model influence is the degree to which the AI model output is the primary determinant of the answer to the question of interest, relative to other contributing evidence. A model that is the sole input driving a patient safety decision carries high model influence. A model whose outputs are one of several independent lines of evidence carries lower model influence.
Decision consequence is the significance of the adverse outcome that would result from an incorrect decision. High decision consequence means that if the model is wrong, the impact on patient safety, drug quality, or regulatory integrity is severe.
These two factors interact. A model with high influence and high decision consequence represents high model risk and requires the most rigorous credibility assessment. A model with low influence and high decision consequence may represent medium risk — as illustrated in the guidance's manufacturing example, where an AI-based visual fill-volume inspection system is paired with independent release testing that reduces its influence even though volume is a critical quality attribute.
The practical implication: the rigor of everything that follows — the documentation burden, the validation requirements, the lifecycle oversight — scales with where a model falls in this matrix.
Section 3 — The Credibility Assessment Plan
Once model risk is assessed, Step 4 of the framework requires developing a credibility assessment plan. This is not a summary document — it is a structured technical record that the guidance expects sponsors to be prepared to submit to or discuss with FDA, depending on the engagement pathway.
The plan must address four interconnected areas.
First, model description: the architecture of the model, its inputs and outputs, the specific modeling approach chosen, and the rationale for that choice. For complex models, this includes feature selection methodology, loss functions, and model parameters.
Second, development data characterization: a detailed account of how training and tuning datasets were assembled, how data independence was maintained, how labels or annotations were established, and how the data is fit for the specific context of use. The guidance is explicit that data must be both relevant — meaning it includes key data elements representative of the target population or process — and reliable, meaning accurate, complete, and traceable. The characterization must also address potential sources of algorithmic bias arising from dataset composition.
Third, training methodology: the learning approach, performance metrics with confidence intervals, techniques used to prevent overfitting, training hyperparameters, and any use of pre-trained models or ensemble methods.
Fourth, model evaluation against independent test data: how the test data was selected and kept independent from development data, the performance metrics used to evaluate the trained model, the uncertainty and confidence of model predictions, and any data drift considerations — the risk that model performance degrades when the inputs encountered in deployment differ from those in training.
Each element of the plan is calibrated to model risk. Low-risk models require proportionally less documentation. High-risk models require all categories in full.
Section 4 — Lifecycle Maintenance: Credibility Is Not Static
One of the guidance's more operationally demanding provisions concerns what happens after a model passes its initial credibility assessment. For models deployed across the drug product lifecycle — particularly in manufacturing but also in ongoing postmarketing and long-running clinical programs — the guidance establishes a lifecycle maintenance obligation.
The premise is straightforward: AI models are data-driven and can be sensitive to variation in their inputs. A model that performs credibly at baseline may not perform the same way six months later if the data it processes has shifted. This phenomenon — data drift — requires ongoing monitoring of model performance metrics against pre-established criteria.
When a model changes, whether incidentally or deliberately, sponsors must evaluate the impact of that change against the model risk and the context of use. Depending on the extent of the change, the credibility assessment plan may need to be partially or fully re-executed, including model retraining and retesting. Material changes may need to be reported to FDA under the applicable postapproval change reporting requirements.
For sponsors building AI into clinical development programs that extend across multiple phases or into postmarketing follow-up, this is a systems design question as much as a documentation question. The infrastructure that supports AI-generated regulatory evidence must be capable of capturing model performance continuously, flagging deviations from expected behavior, and producing the documentation trail that a lifecycle maintenance review requires.
Section 5 — Early Engagement and the Iterative Model
The guidance strongly encourages sponsors to engage with FDA before executing a credibility assessment plan, not after. Early engagement serves two purposes: it allows FDA to provide feedback on the model risk assessment and the proposed credibility assessment activities before significant resources are committed, and it surfaces potential challenges early enough to address them without disrupting the development program.
The guidance provides a detailed table of engagement pathways calibrated to the intended use of the AI model. Sponsors interested in AI use in novel clinical trial designs can engage through the Complex Innovative Trial Design (CID) meeting program. Those using AI in model-informed drug development have access to the MIDD paired meeting program. Sponsors deploying AI in manufacturing have dedicated early engagement channels through CDER's Emerging Technology Program and CBER's Advanced Technologies Team.
For AI use cases in postmarketing pharmacovigilance, the guidance notes that detailed processes and documentation are typically not submitted to FDA proactively but must be maintained and made available on inspection. That availability requirement has direct consequences for documentation infrastructure.
Section 6 — Infrastructure Implications
The credibility assessment framework does not exist in isolation from the clinical data systems that support a trial. Meeting its requirements depends on what those systems are designed to capture, retain, and produce on demand.
The data reliability standard the guidance establishes — accurate, complete, and traceable — maps directly onto audit trail requirements. Development data used to train a model must have a documented provenance chain. The model's outputs, when they influence a regulatory determination, must be linked to the inputs that generated them. Performance monitoring over the lifecycle must be recorded in a format that survives inspection.
An event-driven clinical data platform, designed to capture every operational event in real time as an immutable record, provides the underlying traceability infrastructure this framework requires. When AI operates within a platform that records not just what data was captured but when, under what conditions, and in response to what triggers, the documentation burden of a credibility assessment becomes a function of system architecture rather than manual reconstruction.
This connection — between the FDA's evidentiary expectations for AI and the design of the platforms in which that AI operates — is where the guidance has its most durable operational consequence. As AI adoption in clinical development accelerates, the credibility of AI-generated regulatory evidence will be determined in part by the integrity of the infrastructure surrounding it.
Conclusion
FDA's January 2025 draft guidance establishes that AI credibility in a regulatory context is a documented, risk-stratified, lifecycle-governed process — not a general posture toward responsible AI use. The seven-step framework it describes sets concrete requirements for model characterization, data documentation, performance evaluation, and ongoing maintenance that apply whenever AI-generated outputs inform a regulatory decision.
For development programs integrating AI across the trial lifecycle, the practical question is whether the data infrastructure surrounding those models is built to produce what the framework requires. The guidance makes clear that the answer to that question will be examined — whether through early engagement, submission review, or inspection.
This post reflects Alethium's analysis of FDA's January 2025 draft guidance for industry: "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products." As a draft guidance, it represents FDA's current thinking and is subject to revision upon finalization.
